医学影像学在食管癌治疗决策中应用的专家共识

2021-01-30 中国医院协会 中华介入放射学电子杂志.2021.9(1):1-8.

食管癌是我国常见的恶性肿瘤之一,其发病率及死亡率分别位居我国恶性肿瘤中的第6 位和第4 位,每年新发和死亡病例分别约为25.6 万及19.3 万人。我国食管癌超过90% 为鳞状细胞癌(简称为&ldqu

中文标题:

医学影像学在食管癌治疗决策中应用的专家共识

发布机构:

中国医院协会

发布日期:

2021-01-30

简要介绍:

食管癌是我国常见的恶性肿瘤之一,其发病率及死亡率分别位居我国恶性肿瘤中的第6 位和第4 位,每年新发和死亡病例分别约为25.6 万及19.3 万人。我国食管癌超过90% 为鳞状细胞癌(简称为“鳞癌”),以中晚期肿瘤为主。尽管近年来靶向药物及免疫检查点抑制剂等治疗方式有突破性进展,但手术切除及放化疗仍然是食管癌的主要治疗方式。根据食管癌治疗前临床分期不同,可采取内镜微创切除、根治性手术切除、新辅助放化疗后手术切除或者单纯放化疗等不同的治疗策略。目前,病理学检查仍然是食管癌诊断的金标准,但医学影像检查结果是食管癌临床分期的主要依据,在食管癌治疗决策中起到关键性的作用。参考国内外研究进展及行业专家意见,中国医院协会介入医学分会就医学影像学在食管癌治疗决策中的选择及应用形成以下共识,供同道参考。

下载附件:

(因为版权问题,不支持下载)

评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1179683, encodeId=122b11e968338, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:26 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179682, encodeId=c6ec11e968269, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:18 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179681, encodeId=c87c11e96819c, content=收藏,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:13 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976004, encodeId=79a79e600413, content=收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88395449657, createdName=ms4000001760817265, createdTime=Wed Jun 23 00:51:24 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973906, encodeId=7e049e3906ab, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/90bb8e5e1e1549578d7e5dcf0325e6a7/6833dbcc30864cabb97fe04f83406e9a.jpg, createdBy=389d2172044, createdName=1205446bm69(暂无昵称), createdTime=Tue Jun 15 22:45:14 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2022-01-02 一己怀

    非常实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1179683, encodeId=122b11e968338, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:26 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179682, encodeId=c6ec11e968269, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:18 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179681, encodeId=c87c11e96819c, content=收藏,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:13 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976004, encodeId=79a79e600413, content=收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88395449657, createdName=ms4000001760817265, createdTime=Wed Jun 23 00:51:24 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973906, encodeId=7e049e3906ab, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/90bb8e5e1e1549578d7e5dcf0325e6a7/6833dbcc30864cabb97fe04f83406e9a.jpg, createdBy=389d2172044, createdName=1205446bm69(暂无昵称), createdTime=Tue Jun 15 22:45:14 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2022-01-02 一己怀

    值得拥有

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1179683, encodeId=122b11e968338, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:26 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179682, encodeId=c6ec11e968269, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:18 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179681, encodeId=c87c11e96819c, content=收藏,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:13 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976004, encodeId=79a79e600413, content=收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88395449657, createdName=ms4000001760817265, createdTime=Wed Jun 23 00:51:24 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973906, encodeId=7e049e3906ab, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/90bb8e5e1e1549578d7e5dcf0325e6a7/6833dbcc30864cabb97fe04f83406e9a.jpg, createdBy=389d2172044, createdName=1205446bm69(暂无昵称), createdTime=Tue Jun 15 22:45:14 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2022-01-02 一己怀

    收藏,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1179683, encodeId=122b11e968338, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:26 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179682, encodeId=c6ec11e968269, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:18 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179681, encodeId=c87c11e96819c, content=收藏,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:13 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976004, encodeId=79a79e600413, content=收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88395449657, createdName=ms4000001760817265, createdTime=Wed Jun 23 00:51:24 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973906, encodeId=7e049e3906ab, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/90bb8e5e1e1549578d7e5dcf0325e6a7/6833dbcc30864cabb97fe04f83406e9a.jpg, createdBy=389d2172044, createdName=1205446bm69(暂无昵称), createdTime=Tue Jun 15 22:45:14 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2021-06-23 ms4000001760817265

    收藏

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1179683, encodeId=122b11e968338, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:26 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179682, encodeId=c6ec11e968269, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:18 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179681, encodeId=c87c11e96819c, content=收藏,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sun Jan 02 02:03:13 CST 2022, time=2022-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976004, encodeId=79a79e600413, content=收藏, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=88395449657, createdName=ms4000001760817265, createdTime=Wed Jun 23 00:51:24 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973906, encodeId=7e049e3906ab, content=值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210925/90bb8e5e1e1549578d7e5dcf0325e6a7/6833dbcc30864cabb97fe04f83406e9a.jpg, createdBy=389d2172044, createdName=1205446bm69(暂无昵称), createdTime=Tue Jun 15 22:45:14 CST 2021, time=2021-06-15, status=1, ipAttribution=)]
    2021-06-15 1205446bm69(暂无昵称)

    值得拥有

    0

拓展阅读

2010ESMO临床实践指南:食管癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

食管癌规范化诊治指南

中国抗癌协会食管癌专业委员会(Chinese Society of Esophagenal Cancer, Chinese Anti-Cancer Association) · 2011-04-01

2011 AUGIS/BSG指南:食管癌与胃癌的处理

大不列颠爱尔兰上消化道外科医师协会(AUGIS,Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland) · 2011-07-24

2012 ASGE 内镜在Barrett食管及其他食管癌前病变中的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2012-12-01

2013 ASEG内镜在食管癌评估与治疗方面的作用

美国胃肠内镜学会(ASGE,American Society for Gastrointestinal Endoscopy) · 2013-03-01

2013 STS指南:食管癌患者的诊断与分期

美国胸外科医师学会(STS,Society of Thoracic Surgeons) · 2013-06-07